3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Thoracic
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Neoplasms
8
Melanoma
8
Pancreatic Neoplasms
7
Neoplasm Metastasis
5
Carcinoma, Non-Small-Cell Lung
5
Uterine Cervical Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor
2
Sarcoma
2
Recurrence
2
Liver Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Advanced Solid Tumor
2
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Salivary Gland Neoplasms
1
Refractory or Recurrent Solid Tumor
1
Pelvic Neoplasms
1
Ovarian Neoplasms
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Mesothelioma, Malignant
1
Interventions
Gemcitabine
15
pembrolizumab
13
Doxorubicin
13
Radiotherapy
12
Docetaxel
9
Nivolumab
8
Filgrastim
7
Cyclophosphamide
7
pazopanib
6
Ifosfamide
6
130-nm albumin-bound paclitaxel
5
Temozolomide
4
Irinotecan
4
Ipilimumab
4
Imatinib Mesylate
4
Albumin-Bound Paclitaxel
4
talimogene laherparepvec
3
surufatinib
3
pegfilgrastim
3
eribulin
3
atezolizumab
3
Vinorelbine
3
Sirolimus
3
Peripheral Blood Stem Cell Transplantation
3
PM 01183
3
Drug Therapy
3
Cisplatin
3
toripalimab
2
spartalizumab
2
selinexor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Sarcoma
×
spartalizumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts